{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:01:32Z","timestamp":1770328892519,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"D1","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of new drugs for diseases is a time-consuming, costly and risky process. In recent years, many drugs could be approved for other indications. This repurposing process allows to effectively reduce development costs, time and, ultimately, save patients\u2019 lives. During the ongoing COVID-19 pandemic, drug repositioning has gained widespread attention as a fast opportunity to find potential treatments against the newly emerging disease. In order to expand this field to researchers with varying levels of experience, we made an effort to open it to all users (meaning novices as well as experts in cheminformatics) by significantly improving the entry-level user experience. The browsing functionality can be used as a global entry point to collect further information with regards to small molecules (\u223c1 million), side-effects (\u223c110 000) or drug-target interactions (\u223c3 million). The drug-repositioning tab for small molecules will also suggest possible drug-repositioning opportunities to the user by using structural similarity measurements for small molecules using two different approaches. Additionally, using information from the Promiscuous 2.0 Database, lists of candidate drugs for given indications were precomputed, including a section dedicated to potential treatments for COVID-19. All the information is interconnected by a dynamic network-based visualization to identify new indications for available compounds. Promiscuous 2.0 is unique in its functionality and is publicly available at http:\/\/bioinformatics.charite.de\/promiscuous2.<\/jats:p>","DOI":"10.1093\/nar\/gkaa1061","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T12:10:39Z","timestamp":1603714239000},"page":"D1373-D1380","source":"Crossref","is-referenced-by-count":34,"title":["PROMISCUOUS 2.0: a resource for drug-repositioning"],"prefix":"10.1093","volume":"49","author":[{"given":"Kathleen","family":"Gallo","sequence":"first","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Institute of Physiology, Structural Bioinformatics Group, Berlin\u00a010117, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-9869","authenticated-orcid":false,"given":"Andrean","family":"Goede","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Institute of Physiology, Structural Bioinformatics Group, Berlin\u00a010117, Germany"}]},{"given":"Andreas","family":"Eckert","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Department of Information Technology, Science IT, Berlin\u00a010117, Germany"}]},{"given":"Barbara","family":"Moahamed","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Department of Information Technology, Science IT, Berlin\u00a010117, Germany"}]},{"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Institute of Physiology, Structural Bioinformatics Group, Berlin\u00a010117, Germany"},{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Department of Information Technology, Science IT, Berlin\u00a010117, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-1031","authenticated-orcid":false,"given":"Bj\u00f6rn-Oliver","family":"Gohlke","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universitaetsmedizin Berlin, Department of Information Technology, Science IT, Berlin\u00a010117, Germany"}]}],"member":"286","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2021010313114760400_B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40360-017-0128-7","article-title":"Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects","volume":"18","author":"Chartier","year":"2017","journal-title":"BMC Pharmacol. Toxicol."},{"key":"2021010313114760400_B2","first-page":"361","article-title":"Drug promiscuity","volume":"46","author":"Guo","year":"2011","journal-title":"Yao Xue Xue Bao"},{"key":"2021010313114760400_B3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2165\/00002018-199411030-00005","article-title":"Mechanisms of unpredictable adverse drug reactions","volume":"11","author":"Rieder","year":"1994","journal-title":"Drug Saf."},{"key":"2021010313114760400_B4","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.2174\/1381612822666160923115828","article-title":"Polypharmacology in precision oncology: current applications and future prospects","volume":"22","author":"Antolin","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"2021010313114760400_B5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/cmdc.201700535","article-title":"Rationalizing promiscuity cliffs","volume":"13","author":"Dimova","year":"2018","journal-title":"ChemMedChem"},{"key":"2021010313114760400_B6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really 802 million dollars?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff. (Millwood)"},{"key":"2021010313114760400_B7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","article-title":"The cost of drug development: a systematic review","volume":"100","author":"Morgan","year":"2011","journal-title":"Health Policy"},{"key":"2021010313114760400_B8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.drudis.2013.03.002","article-title":"Compound promiscuity: what can we learn from current data","volume":"18","author":"Hu","year":"2013","journal-title":"Drug Discov. Today"},{"key":"2021010313114760400_B9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021010313114760400_B10","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3389\/fphar.2018.01068","article-title":"Editorial: drug repositioning: current advances and future perspectives","volume":"9","author":"Nishimura","year":"2018","journal-title":"Front Pharmacol"},{"key":"2021010313114760400_B11","doi-asserted-by":"crossref","first-page":"101303","DOI":"10.1016\/j.isci.2020.101303","article-title":"Current status of COVID-19 therapies and drug repositioning applications","volume":"23","author":"Altay","year":"2020","journal-title":"iScience"},{"key":"2021010313114760400_B12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"Guy","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"2021010313114760400_B13","doi-asserted-by":"crossref","first-page":"105969","DOI":"10.1016\/j.ijantimicag.2020.105969","article-title":"Drug repositioning is an alternative for the treatment of coronavirus COVID-19","volume":"55","author":"Serafin","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2021010313114760400_B14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"2021010313114760400_B15","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B16","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/bib\/bbw136","article-title":"Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning","volume":"19","author":"Shameer","year":"2018","journal-title":"Brief. Bioinform."},{"key":"2021010313114760400_B18","doi-asserted-by":"crossref","first-page":"170029","DOI":"10.1038\/sdata.2017.29","article-title":"A standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci. Data"},{"key":"2021010313114760400_B19","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1021\/acs.jcim.9b00365","article-title":"EK-DRD: a comprehensive database for drug repositioning inspired by experimental knowledge","volume":"59","author":"Zhao","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"2021010313114760400_B20","doi-asserted-by":"crossref","first-page":"e0177743","DOI":"10.1371\/journal.pone.0177743","article-title":"DrugSig: A resource for computational drug repositioning utilizing gene expression signatures","volume":"12","author":"Wu","year":"2017","journal-title":"PLoS One"},{"key":"2021010313114760400_B21","doi-asserted-by":"crossref","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","article-title":"SuperDRUG2: a one stop resource for approved\/marketed drugs","volume":"46","author":"Siramshetty","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B22","doi-asserted-by":"crossref","first-page":"D1113","DOI":"10.1093\/nar\/gkr912","article-title":"SuperTarget goes quantitative: update on drug-target interactions","volume":"40","author":"Hecker","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B23","doi-asserted-by":"crossref","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","article-title":"The SIDER database of drugs and side effects","volume":"44","author":"Kuhn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B24","doi-asserted-by":"crossref","first-page":"W26","DOI":"10.1093\/nar\/gku477","article-title":"SuperPred: update on drug classification and target prediction","volume":"42","author":"Nickel","year":"2014","journal-title":"Nucleic. Acids. Res."},{"key":"2021010313114760400_B25","doi-asserted-by":"crossref","first-page":"D1121","DOI":"10.1093\/nar\/gkx1076","article-title":"Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics","volume":"46","author":"Li","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/ci010132r","article-title":"Reoptimization of MDL keys for use in drug discovery","volume":"42","author":"Durant","year":"2002","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"2021010313114760400_B27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"2021010313114760400_B28","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"2021010313114760400_B29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13321-015-0085-3","article-title":"ChemDoodle Web Components: HTML5 toolkit for chemical graphics, interfaces, and informatics","volume":"7","author":"Burger","year":"2015","journal-title":"J. Cheminform"},{"key":"2021010313114760400_B30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/ci00057a005","article-title":"SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules","volume":"28","author":"Weininger","year":"1988","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"2021010313114760400_B31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60 years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021010313114760400_B32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/pgmj.70.819.37","article-title":"Warfarin treatment and migraine","volume":"70","author":"Suresh","year":"1994","journal-title":"Postgrad. Med. J."},{"key":"2021010313114760400_B33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/2193-1801-2-48","article-title":"An unusual case report on the possible role of Warfarin in migraine prophylaxis","volume":"2","author":"Russo","year":"2013","journal-title":"Springerplus"},{"key":"2021010313114760400_B34","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10072-011-0926-4","article-title":"Migraine responsive to warfarin: an update on anticoagulant possible role in migraine prophylaxis","volume":"33","author":"Maggioni","year":"2012","journal-title":"Neurol. Sci."},{"key":"2021010313114760400_B35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1532-5415.1978.tb01222.x","article-title":"Huntington's disease: improvement with an anticoagulant-psychotherapy regimen","volume":"26","author":"Walsh","year":"1978","journal-title":"J. Am. Geriatr. Soc."},{"key":"2021010313114760400_B36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1756-185X.2009.01395.x","article-title":"Reduced bone density in patients on long-term warfarin","volume":"12","author":"Rezaieyazdi","year":"2009","journal-title":"Int. J. Rheum. Dis."},{"key":"2021010313114760400_B37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbacli.2015.08.002","article-title":"Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis","volume":"4","author":"Namba","year":"2015","journal-title":"BBA Clin"},{"key":"2021010313114760400_B38","doi-asserted-by":"crossref","first-page":"bcr2015210203","DOI":"10.1136\/bcr-2015-210203","article-title":"Warfarin-related recurrent knee haemarthrosis treated with arterial embolisation and intra-articular injection of tranexamic acid","volume":"2015","author":"Kunugiza","year":"2015","journal-title":"BMJ Case Rep."},{"key":"2021010313114760400_B39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/art.1780190117","article-title":"Hemarthrosis associated with sodium warfarin therapy","volume":"19","author":"Wild","year":"1976","journal-title":"Arthritis Rheum."},{"key":"2021010313114760400_B40","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","article-title":"Association of warfarin use with lower overall cancer incidence among patients older than 50 years","volume":"177","author":"Haaland","year":"2017","journal-title":"JAMA Intern Med."},{"key":"2021010313114760400_B41","doi-asserted-by":"crossref","DOI":"10.1111\/andr.12836","article-title":"Worse progression of COVID-19 in men: Is testosterone a key factor?","author":"Giagulli","year":"2020","journal-title":"Andrology"},{"key":"2021010313114760400_B42","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de\u00a0Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"2021010313114760400_B43","first-page":"S11","article-title":"Loperamide: a pharmacological review","volume":"7","author":"Baker","year":"2007","journal-title":"Rev. Gastroenterol. Disord."},{"key":"2021010313114760400_B44","doi-asserted-by":"crossref","first-page":"W350","DOI":"10.1093\/nar\/gkz391","article-title":"Drug ReposER: a web server for predicting similar amino acid arrangements to known drug binding interfaces for potential drug repositioning","volume":"47","author":"Ab\u00a0Ghani","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Nucleic Acids Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1373\/35363935\/gkaa1061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nar\/article-pdf\/49\/D1\/D1373\/35363935\/gkaa1061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T18:13:40Z","timestamp":1609697620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nar\/article\/49\/D1\/D1373\/5983618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":44,"journal-issue":{"issue":"D1","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2021,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/nar\/gkaa1061","relation":{},"ISSN":["0305-1048","1362-4962"],"issn-type":[{"value":"0305-1048","type":"print"},{"value":"1362-4962","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,8]]},"published":{"date-parts":[[2020,11,16]]}}}